RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address high unmet medical needs. We believe that we are well positioned to compete successfully using our RNAi technology platform for the development of novel therapeutics to improve patients’ lives. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.
PROPRIETARY SELF-DELIVERING RNAi (sd-rxRNA®) TECHNOLOGY PLATFORM
Provided by Nasdaq.
Jun 15 from 4:00 PM EDT to Jun 16, 2017Marcum MicroCap Conference
Jun 2, 2017 at 1:10 PM EDT3rd Annual Immuno-Oncology BD&L and Investment Forum
May 11, 2017 at 4:30 PM EDTRXi Pharmaceuticals First Quarter 2017 Earnings Call